By Counterforce Health Team in Enhertu (fam-trastuzumab deruxtecan-nxki) —

Humana's Coverage Criteria for Enhertu in New Jersey: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Enhertu Covered by Humana in New Jersey

Humana requires prior authorization for Enhertu (fam-trastuzumab deruxtecan-nxki) with HER2 testing, prior therapy documentation, and ILD monitoring plan. Submit via Availity provider portal with pathology reports and clinical notes. Standard approval takes 7 days; expedited 72 hours. If denied, appeal within 65 days internally, then use New Jersey's IHCAP external review via Maximus Federal Services.

First step today: Verify your Humana plan covers Enhertu on Tier 4 specialty formulary and confirm network infusion center access.

Table of Contents

  1. Coverage Overview
  2. Prior Authorization Requirements
  3. Medical Necessity Criteria
  4. Step Therapy and Exceptions
  5. Site of Care Requirements
  6. Appeals Process in New Jersey
  7. Common Denial Reasons and Solutions
  8. Costs and Patient Support
  9. FAQ

Coverage Overview

Humana covers Enhertu as a Tier 4 specialty medication requiring prior authorization across all plan types—Medicare Advantage, Medicare Part D, and commercial plans. The drug is billed under the medical benefit using J-code J9358 for provider-administered infusions.

Plan Types and Policies

  • Medicare Advantage: Standard PA process with 90-day grace period for new enrollees already on treatment
  • Commercial Plans: Similar PA requirements with state-specific appeal rights
  • Medicaid (NJ FamilyCare): Covered with PA; follows same clinical criteria
Note: Humana is eliminating approximately one-third of prior authorizations by January 2026, but oncology specialties like Enhertu will likely remain under PA requirements.

Prior Authorization Requirements

Coverage at a Glance

Requirement Details Documentation Needed Source
Prior Authorization Required for all plans HER2 testing, prior therapy records Humana PA List
Formulary Tier Tier 4 Specialty Prescription from oncologist Humana Drug List
Step Therapy Not required for most plans Prior HER2 agent failures Coverage Policy
Specialty Pharmacy Accredo or CenterWell Provider enrollment forms Humana Specialty

Submission Process

Fastest submission method: Availity provider portal (preferred for electronic submissions)

Alternative methods:

  • CoverMyMeds for pharmacy PA
  • Fax to provider-specific number
  • Phone: 866-421-5663

Timeline expectations:

  • Standard decisions: 7 days
  • Expedited (urgent/life-threatening): 72 hours

Medical Necessity Criteria

FDA-Approved Indications Covered

Enhertu must be prescribed for an FDA-approved indication with proper biomarker testing:

  1. HER2-positive breast cancer: Unresectable/metastatic, after prior anti-HER2 therapy
  2. HER2-low breast cancer: IHC 1+ or IHC 2+/ISH-, after prior chemotherapy
  3. HER2-ultralow breast cancer: IHC 0 with membrane staining, HR-positive
  4. HER2-mutant NSCLC: After prior systemic treatment
  5. HER2-positive gastric/GEJ cancer: After prior trastuzumab-based regimen

Required Biomarker Testing

All indications require FDA-approved companion diagnostics:

  • Breast cancer: PATHWAY anti-HER2/neu (4B5) assay for IHC and/or HER2 Dual ISH
  • NSCLC: HER2 mutation testing
  • Gastric: HER2-positive status confirmation

Clinical Documentation Requirements

Essential elements for approval:

Element Details
Diagnosis Codes Primary: C50.- (breast), C78.- (NSCLC), C16.- (gastric)
HER2 Status Include Z17.31 (HER2-positive status) for stronger justification
Drug Coding J9358 (1 mg units); NDC 65597-0406-01
Dosing 5.4 mg/kg IV every 21 days
Prior Therapies Document failures/intolerance to required agents

Step Therapy and Exceptions

Good news: Most Humana Medicare Advantage plans show no step therapy requirements for Enhertu, unlike many other oncology drugs.

When Step Therapy May Apply

For commercial plans, you may need to document:

  • Prior trastuzumab-based therapy (for HER2-positive indications)
  • Chemotherapy trials (for HER2-low breast cancer)
  • Systemic therapy attempts (for NSCLC)

Medical Exception Pathways

If step therapy is required, exceptions are granted for:

  • Contraindications to required first-line agents
  • Previous intolerance with documented adverse effects
  • Clinical urgency where delay would be detrimental
Clinician Corner: Include specific details about why standard therapies failed (progression dates, toxicity grades, hospitalization records) rather than generic statements.

Site of Care Requirements

Network Restrictions

Enhertu must be administered at:

  • Network infusion centers
  • Hospital outpatient departments
  • Designated oncology facilities

Not covered at: Retail pharmacies, patient homes, or out-of-network facilities

Specialty Pharmacy Coordination

Primary network: Accredo (for oncology) Alternative: CenterWell Specialty Pharmacy

The specialty pharmacy coordinates:

  • Drug delivery to infusion site
  • Insurance verification
  • Patient education and support
  • Refill management

Appeals Process in New Jersey

Internal Appeals with Humana

Timeline: File within 65 days of denial notice

Required documents:

  • Original denial letter
  • Updated medical records
  • Peer-reviewed literature supporting use
  • Prescriber attestation letter

Decision timeline:

  • Standard: 30-60 days
  • Expedited: 72 hours (for urgent cases)

External Review via New Jersey IHCAP

If Humana upholds the denial, New Jersey residents can access the state's Independent Health Care Appeals Program (IHCAP).

Key details:

  • Administrator: Maximus Federal Services (IURO)
  • Filing deadline: 4 months from final internal denial
  • Cost: Free to patients
  • Success rate: External appeals favor consumers in approximately 50% of cases nationwide

IHCAP Process Steps

  1. Complete internal appeals with Humana first
  2. Download form from NJ DOBI
  3. Submit online at https://njihcap.maximus.com
  4. Preliminary review: 5 business days
  5. Final decision: 45 days standard, 48 hours expedited

The Independent Health Care Appeals Program (IHCAP) represents one of New Jersey's most valuable patient protections. When insurance companies deny coverage for expensive treatments like Enhertu, having independent medical experts review those decisions levels the playing field. Counterforce Health helps patients and providers navigate these complex appeal processes by turning denial letters into targeted, evidence-backed rebuttals that address payer-specific requirements.

Common Denial Reasons and Solutions

Denial Reason Solution Documents Needed
Missing HER2 status Submit complete pathology report CLIA-certified lab results with IHC/ISH
Insufficient prior therapy Document treatment timeline Pharmacy records, infusion logs, progression notes
ILD risk concerns Include monitoring plan Baseline CT chest, PFTs, respiratory consult
Non-network site Verify infusion center Provider directory, network confirmation
Experimental/investigational Cite FDA approval FDA label, NCCN guidelines
From our advocates: We've seen denials overturned when providers include specific progression dates and imaging reports rather than just stating "disease progression." Concrete evidence like "CT showed 25% increase in liver lesions on [date]" carries more weight than general statements.

Costs and Patient Support

Manufacturer Support Programs

Enhertu Co-pay Program:

  • Eligible patients may pay as little as $25 per treatment
  • Available for commercially insured patients
  • Not valid for Medicare or Medicaid

Patient Assistance:

Additional Resources

  • NJ DOBI Consumer Hotline: 1-800-446-7467
  • IHCAP-specific questions: 1-888-393-1062
  • Humana Member Services: Number on insurance card

When appeals become complex, services like Counterforce Health can help by analyzing denial letters and crafting point-by-point rebuttals that address each payer's specific coverage criteria and procedural requirements.

FAQ

Q: How long does Humana prior authorization take for Enhertu in New Jersey? A: Standard PA decisions take 7 days; expedited reviews for urgent cases are completed within 72 hours.

Q: What if Enhertu is non-formulary on my Humana plan? A: Request a formulary exception with medical necessity documentation. Humana supports non-formulary coverage based on clinical need.

Q: Can I request an expedited appeal if my cancer is progressing? A: Yes, both Humana internal appeals and New Jersey IHCAP external reviews offer expedited timelines for urgent medical situations.

Q: Does step therapy apply if I failed HER2 therapies outside New Jersey? A: Treatment history from any state counts toward step therapy requirements. Provide complete documentation of prior therapies and outcomes.

Q: What happens if IHCAP overturns Humana's denial? A: The decision is binding—Humana must provide coverage immediately and cannot delay implementation.

Q: Are there income limits for manufacturer copay assistance? A: Yes, most programs have household income caps. Contact the manufacturer directly for current eligibility criteria.

Sources and Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies and appeal procedures may change. Always verify current requirements with your insurance plan and consult healthcare providers for medical decisions. For personalized assistance with insurance appeals, consider consulting qualified patient advocacy services.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.